These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31332191)

  • 41. Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment.
    Adham M; Greijer AE; Verkuijlen SA; Juwana H; Fleig S; Rachmadi L; Malik O; Kurniawan AN; Roezin A; Gondhowiardjo S; Atmakusumah D; Stevens SJ; Hermani B; Tan IB; Middeldorp JM
    Clin Cancer Res; 2013 Apr; 19(8):2175-86. PubMed ID: 23493345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
    Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
    Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions.
    Gurtsevitch VE; Senyuta NB; Ignatova AV; Lomaya MV; Kondratova VN; Pavlovskaya AI; Dushenkina TE; Maximovich DM; Smirnova KV; Mudunov AM; Lichtenstein AV
    J Gen Virol; 2017 Aug; 98(8):2118-2127. PubMed ID: 28786806
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma.
    Zhou H; Lu T; Guo Q; Chen Y; Chen M; Chen Y; Lin Y; Chen C; Ma L; Xu Y; Lin S; Pan J
    Cancer Med; 2020 Apr; 9(8):2732-2741. PubMed ID: 32090498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating Epstein-Barr virus microRNA profile reveals novel biomarker for nasopharyngeal carcinoma diagnosis.
    Wu L; Wang J; Zhu D; Zhang S; Zhou X; Zhu W; Zhu J; He X
    Cancer Biomark; 2020; 27(3):365-375. PubMed ID: 31958073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical applications of plasma Epstein-Barr virus DNA analysis and protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA.
    Chan KC; Lo YM
    Methods Mol Biol; 2006; 336():111-21. PubMed ID: 16916257
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
    Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
    Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein-Barr virus associated nasopharyngeal carcinoma.
    Liu L; Zuo L; Yang J; Xin S; Zhang J; Zhou J; Li G; Tang J; Lu J
    Cancer Med; 2019 Jun; 8(6):3142-3151. PubMed ID: 31063269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging.
    Tang LQ; Chen QY; Fan W; Liu H; Zhang L; Guo L; Luo DH; Huang PY; Zhang X; Lin XP; Mo YX; Liu LZ; Mo HY; Li J; Zou RH; Cao Y; Xiang YQ; Qiu F; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Mai HQ
    J Clin Oncol; 2013 Aug; 31(23):2861-9. PubMed ID: 23857969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical value of a plasma Epstein-Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis.
    Peng H; Li Z; Long Y; Li J; Liu Z; Zhou R
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31484795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
    Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
    Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maximal standard uptake values of
    Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
    BMC Cancer; 2019 Sep; 19(1):908. PubMed ID: 31511059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early screening of nasopharyngeal carcinoma.
    Yuan Y; Ye F; Wu JH; Fu XY; Huang ZX; Zhang T
    Head Neck; 2023 Oct; 45(10):2700-2709. PubMed ID: 37552128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
    Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma.
    King AD; Woo JKS; Ai QY; Chan JSM; Lam WKJ; Tse IOL; Bhatia KS; Zee BCY; Hui EP; Ma BBY; Chiu RWK; van Hasselt AC; Chan ATC; Lo YMD; Chan KCA
    Ann Oncol; 2019 Jun; 30(6):977-982. PubMed ID: 30912815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population.
    Hutajulu SH; Indrasari SR; Indrawati LP; Harijadi A; Duin S; Haryana SM; Steenbergen RD; Greijer AE; Middeldorp JM
    Mol Cancer; 2011 May; 10():48. PubMed ID: 21535891
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma.
    Jiang C; Chen J; Xie S; Zhang L; Xiang Y; Lung M; Kam NW; Kwong DL; Cao S; Guan XY
    Int J Cancer; 2018 Dec; 143(12):3209-3217. PubMed ID: 29971780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and analytical validation of a novel nasopharynx swab-based Epstein-Barr virus C promoter methylation quantitative assay for nasopharyngeal carcinoma detection.
    Wu ZC; Lin KN; Li XQ; Ye X; Chen H; Tao J; Zhou HN; Chen WJ; Lin DF; Xie SH; Cao SM
    Clin Chem Lab Med; 2024 Jan; 62(1):187-198. PubMed ID: 37531579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.
    Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL
    Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.